摘要
甲状腺乳头状癌(papillary thyroidcar cinoma-PTC)是最常见的甲状腺恶性肿瘤,目前研究提示BRAF-T1799A突变与PTC的发生、发展密切相关。本文结合目前BRAF-T1799A在PTC发病、风险分级、临床管理、手术方式的选择,术后放射性碘消融治疗及随访等相关研究,综述BRAF-T1799A突变在PTC的发病、诊断、治疗、预后方面的临床前景。
Papillary thyroid carcinoma （PTC） is the most common type of thyroid malignancy that frequently harbors the oncogenic BRAF-T1799A mutation. The present review is to provide a clinical front view of the BRAF-T1799A mutation in the preoperative initial of operation, postoperative decisions about appropriate radioiodine treatment, thyroid-stimulating hormone suppression, and to selections of appropriate follow-up for PTC recurrence.
出处
《临床医学工程》
2011年第12期1987-1989,共3页
Clinical Medicine & Engineering
